Cargando…
Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes
Breast cancer patients increasingly undergo genetic testing. To examine chemotherapy indications for germline pathogenic variant (PV) carriers, we linked results of germline testing to Georgia and California Surveillance, Epidemiology, and End Results registry records, including 21-gene recurrence s...
Autores principales: | Kurian, Allison W, Ward, Kevin C, Abrahamse, Paul, Hamilton, Ann S, Katz, Steven J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785044/ https://www.ncbi.nlm.nih.gov/pubmed/33426465 http://dx.doi.org/10.1093/jncics/pkaa083 |
Ejemplares similares
-
Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment
por: Kurian, Allison W, et al.
Publicado: (2022) -
Pathogenic germline variants in
SMARCA4
and further cancer predisposition genes in early onset ovarian cancer
por: Herold, Natalie, et al.
Publicado: (2023) -
Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series
por: Sukumar, Jasmine, et al.
Publicado: (2021) -
Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes
por: Mavaddat, Nasim, et al.
Publicado: (2022) -
Pathogenicity and Penetrance of Germline SDHA Variants in Pheochromocytoma and Paraganglioma (PPGL)
por: Maniam, Pavithran, et al.
Publicado: (2018)